Inclusion Criteria::

   - 21-item HAM-D score of 20 or above.

   - If currently taking antipsychotic, antidepressant, anticonvulsant, and/or
   mood-stabilizing medications, must be stable on the medication for at least three
   weeks prior to entering the study.

   - At least 2 failed antidepressant medication trials of adequate dose and duration.

   - Between 18 and 75 years of age.

   - Not currently pregnant or trying to become pregnant. Exclusion Criteria:-History of
   schizophrenia or other psychotic disorders.

   - Transcranial magnetic stimulation treatment or ECT in the 3 months prior to starting
   the study.

   - History of vagus nerve stimulation treatment.

   - No unstable or untreated cardiovascular disease, hypertension, or endocrine disorder.

   - Current use of oral contraceptives or any other drug that may result in adverse
   drug-mifepristone interactions effects (including Amiodarone, Clarithromycin,
   Erythromycin, Fluconazole, Fluvoxamine, Indinavir, Intraconazole, Ketoconazole,
   Metronidazole, Miconazole, Nefazodone, Nelfinavir, Norfloxacin, Omeprazole, Quinine,
   Ritonavir, Saquinavir, Troleandomycin, Zafirlukast, Carbamazepine, Dexamethasone,
   Ethosuximide, Phenobarbital, Phenytoin, Primidone, Rifabutin, Rifampin, Troglitazone).
   A 30-day wash-out period for oral contraceptives is required before mifepristone
   begins.

   - Previous allergic reaction to mifepristone or drugs of similar chemical structure.